PCMT1 and breast cancer: The results showed that low expression of PCMT1 was significantly correlated with longer OS (HR = 1.38, 95% CI: 1.14–1.67, P = 0.00072), RFS (HR = 1.23, 95% CI: 1.11–1.37, P = 4.9e − 05), and PPS (HR = 1.44, 95% CI: 1.14–1.82, P = 0.0023) in breast cancer patients, but not significantly correlated with DMFS (HR = 0.87, 95% CI: 0.73–1.04, P = 0.12) (Figure 6).